Results from TRITON2: Treatment of mCRPC with Rucaparib - Alan Bryce

(Length of Discussion: 8 min)

Charles Ryan and Alan Bryce discuss TRITON2 results that provide a compelling rationale for evaluating rucaparib, a potent PARP1, PARP2 and PARP3 inhibitor, in patients with mCRPC associated with homologous recombination deficiency.  Alan presents the molecular selection criteria, the design of the trial and the initial look at the first 85 patients in this study of heavily pretreated patients.

Biographies:

Alan H. Bryce, MD, Medical Director of the Genomic Oncology Clinic at Mayo Clinic, Arizona

Charles J. Ryan, MD